Amid a swell of regulatory successes in the myasthenia gravis arena this decade, Amgen is wading into the fray with a new ...

Drug development in biotechnology takes time. A lot of time. On average, it takes 10 to 15 years to take a medicine from ...

After three decades spent rising through the ranks of sales and marketing teams at major pharmas, Chris Boulton is taking the ...

Generalized myasthenia gravis is Uplizna’s second new indication this year, after the FDA cleared the anti-CD19 antibody for ...

Amgen (AMGN) “announced that the FDA has approved UPLIZNA, inebilizumab-cdon, for the treatment of generalized myasthenia ...

The Muscular Dystrophy Association (MDA) recognizes the U.S. Food and Drug Administration (FDA) approval of Amgen’s UPLIZNA ® (inebilizumab-cdon) for the treatment of generalized myasthenia gravis ...

HSBC raised the firm’s price target on Amgen (AMGN) to $425 from $381 and keeps a Buy rating on the shares as part of a 2026 ...

Curious if Amgen is worth your investment dollars right now? Let’s take a clear-eyed look at where the stock stands and ...

Amgen Inc. is at least fairly valued, with improving balance sheet metrics and a robust growth pipeline offsetting looming ...

The FDA’s approval of Uplizna for antibody-positive generalized myasthenia gravis introduces a twice-yearly CD19-targeted therapy option for the rare autoimmune condition. The FDA has approved Amgen’s ...

Amgen’s stock narrative is shifting, as reflected in a slight but noticeable increase in the consensus analyst price target ...

Amgen received approval from the Food and Drug Administration for its treatment for generalized myasthenia gravis, an autoimmune disorder. The pharmaceutical company said Thursday the drug Uplizna has ...